Patents by Inventor Sudhir Agrawal

Sudhir Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
    Publication number: 20060211641
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotideand having an accessible 5? end.
    Type: Application
    Filed: July 1, 2005
    Publication date: September 21, 2006
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar Kandimalla
  • Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
    Patent number: 7105495
    Abstract: The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: September 12, 2006
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla
  • Modified protein kinase A-specific oligonucleotides and methods of their use
    Patent number: 7074768
    Abstract: Disclosed are synthetic, modified oligonucleotides complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RI?. The modified oligonucleotides have from about 15 to about 30 nucleotides and are hybrid, inverted hybrid, or inverted chimeric oligonucleotides. Also disclosed are therapeutic compositions containing such oligonucleotides and methods of using the same. In addition, therapeutic compositions and methods of their use are described which are directed to a synergistic effect resulting from the combination of oligonucleotides of the invention and other therapeutic compositions and methods.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: July 11, 2006
    Assignee: Idera Pharmaceuticals, Inc.
    Inventor: Sudhir Agrawal
  • Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
    Publication number: 20060142556
    Abstract: The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
    Type: Application
    Filed: November 15, 2005
    Publication date: June 29, 2006
    Inventor: Sudhir Agrawal
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Publication number: 20060142224
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Application
    Filed: October 27, 2003
    Publication date: June 29, 2006
    Inventors: Ekambar Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Publication number: 20060135454
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Application
    Filed: October 27, 2003
    Publication date: June 22, 2006
    Inventors: Ekambar Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Synergistic inhibition of VEGF and modulation of the immune response
    Publication number: 20060105979
    Abstract: The invention provides methods and compositions for treating asthma and allergy by inhibiting VEGF expression and modulating the immune system from a Th2 response to a Th1 response.
    Type: Application
    Filed: November 8, 2005
    Publication date: May 18, 2006
    Inventors: Sudhir Agrawal, Ekambar Kandimalla
  • Hybrid oligonucleotide phosphorothioates
    Patent number: 7045609
    Abstract: The invention provides hybrid oligonucleotides having phosphorothioate or phosphorodithioate internucleotide linkages, and both deoxyribonucleosides and ribonucleosides or 2?-substituted ribonucleosides. Such hybrid oligonucleotides have superior properties of duplex formation with RNA, nuclease resistance, and RNase H activation.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: May 16, 2006
    Assignee: University of Massachusetts Worcester
    Inventors: Valeri Metelev, Sudhir Agrawal
  • Immunostimulatory oligonucleotide multimers
    Publication number: 20060094680
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Application
    Filed: September 22, 2005
    Publication date: May 4, 2006
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Immunostimulatory oligonucleotide multimers
    Publication number: 20060094681
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Application
    Filed: September 22, 2005
    Publication date: May 4, 2006
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
    Publication number: 20060074040
    Abstract: The invention provides optimized methods and compositions for enhancing the immune response caused by immunostimulatory compounds used for the treatment of disease such as, but not limited to, treatment of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies and infectious diseases in a patient. The optimized methods according to the invention provide synergy between the therapeutic effects of immunostimulatory oligonucleotides and immunomer compounds in accordance with the invention, and the therapeutic effect of cytokine immunotherapy and/or chemotherapeutic agents and/or radiation.
    Type: Application
    Filed: July 15, 2004
    Publication date: April 6, 2006
    Inventors: Ekambar Kandimalla, Sudhir Agrawal
  • Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
    Publication number: 20060052319
    Abstract: This invention relates to the fields of molecular biology and oncology. More particularly, this invention relates to the sensitization of cancerous cells to therapeutic agents. The invention provides methods, compositions, and formulations for potentiating or enhancing the toxicity of various cytotoxins and oxidizing agents, and of reducing the resistance and proliferation rate of cancer cells. It also provides various compositions and therapeutic formulations useful as anticancer agents.
    Type: Application
    Filed: April 3, 2001
    Publication date: March 9, 2006
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, David Bregman, Sridhar Mani, Yi Lu
  • Immunostimulatory oligonucleotide multimers
    Publication number: 20060025365
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Application
    Filed: July 1, 2005
    Publication date: February 2, 2006
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Immunostimulatory oligonucleotide multimers
    Publication number: 20060019919
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Application
    Filed: July 1, 2005
    Publication date: January 26, 2006
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
    Publication number: 20060019909
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: August 25, 2004
    Publication date: January 26, 2006
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu, Lakshmi Bhagat
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
    Publication number: 20060019918
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: July 1, 2005
    Publication date: January 26, 2006
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar Kandimalla
  • Immunostimulatory oligonucleotide multimers
    Publication number: 20060014713
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Application
    Filed: June 15, 2005
    Publication date: January 19, 2006
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
    Publication number: 20050266015
    Abstract: The invention relates to the therapeutic use of a second generation immunomodulatory oligonucleotide in combination with HIV-1 antigen or immunogen to enhance the ability to reduce the risk HIV infection and to control the progression of HIV infection to prevent AIDS Related Complex (ARC) and AIDS.
    Type: Application
    Filed: March 11, 2005
    Publication date: December 1, 2005
    Inventors: Mario Clerici, Richard Bartholomew, Dorothy Bray, Ekambar Kandimalla, Sudhir Agrawal
  • Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
    Publication number: 20050222072
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers on mucosal innate immunity as well as adjuvant activity using ovalbumin (OVA) as an antigen through administration to the mucosal lining.
    Type: Application
    Filed: February 17, 2005
    Publication date: October 6, 2005
    Inventors: Daqing Wang, Ekambar Kandimalla, Sudhir Agrawal, Fu-Gang Zhu
  • MDM2-specific antisense oligonucleotides
    Patent number: 6946447
    Abstract: The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent. The invention further provides in vitro and in vivo models to evaluate the therapeutic effectiveness of a recently identified anti-human-MDM2 antisense oligonucleotide in the treatment of human colorectal cancers.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: September 20, 2005
    Assignee: Hybridon, Inc.
    Inventors: Jiandong Chen, Sudhir Agrawal, Ruiwen Zhang